Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Keros Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -572.1%. For fiscal 2025 it was 35.7%, against -101319.2% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.7% | +101354.9 |
| FY2023 | Dec 31, 2023 | -101319.2% | −101026.9 |
| FY2021 | Dec 31, 2021 | -292.3% | −168.9 |
| FY2019 | Dec 31, 2019 | -123.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -74087.5% | −74157.8 |
| Q4 FY2025 | Dec 31, 2025 | -6173.9% | +21968.0 |
| Q3 FY2025 | Sep 30, 2025 | -51.5% | +492948.5 |
| Q2 FY2025 | Jun 30, 2025 | -169.0% | −134.3 |
| Q1 FY2025 | Mar 31, 2025 | 70.3% | +15692.3 |
| Q4 FY2023 | Dec 31, 2023 | -28142.0% | −28031.9 |
| Q3 FY2023 | Sep 30, 2023 | -493000.0% | −492858.0 |
| Q4 FY2021 | Dec 31, 2021 | -34.7% | +79.4 |
| Q2 FY2021 | Jun 30, 2021 | -15622.0% | −15494.7 |
| Q4 FY2019 | Dec 31, 2019 | -110.0% | – |
| Q3 FY2019 | Sep 30, 2019 | -142.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -114.1% | – |
| Q1 FY2019 | Mar 31, 2019 | -127.3% | – |
See a number that looks wrong?